Mesa Laboratories, Inc. $MLAB is Roubaix Capital LLC’s 10th Largest Position

Roubaix Capital LLC lifted its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 30.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,115 shares of the medical instruments supplier’s stock after buying an additional 16,926 shares during the quarter. Mesa Laboratories makes up approximately 3.0% of Roubaix Capital LLC’s investment portfolio, making the stock its 10th largest position. Roubaix Capital LLC’s holdings in Mesa Laboratories were worth $6,376,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Royal Bank of Canada grew its stake in Mesa Laboratories by 1.2% in the 1st quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier’s stock valued at $3,652,000 after acquiring an additional 353 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in Mesa Laboratories during the first quarter worth $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Mesa Laboratories by 4.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock worth $364,000 after acquiring an additional 143 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Mesa Laboratories by 3.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier’s stock valued at $2,370,000 after purchasing an additional 685 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in Mesa Laboratories by 1.5% during the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after purchasing an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $94.00.

Mesa Laboratories Stock Performance

NASDAQ MLAB opened at $97.94 on Friday. The company has a market cap of $540.63 million, a PE ratio of 81.62 and a beta of 0.93. The stock’s 50 day simple moving average is $101.02 and its 200-day simple moving average is $93.41. Mesa Laboratories, Inc. has a 1-year low of $55.45 and a 1-year high of $113.99. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing the consensus estimate of $1.78 by ($0.25). Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The firm had revenue of $63.72 million for the quarter, compared to analysts’ expectations of $65.21 million. During the same quarter in the previous year, the firm posted ($1.31) earnings per share.

Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories’s payout ratio is 53.33%.

Insiders Place Their Bets

In other news, CAO Lyndsey Elizabeth Crennen sold 442 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $39,559.00. Following the completion of the sale, the chief accounting officer owned 2,020 shares of the company’s stock, valued at $180,790. This represents a 17.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO John Sakys sold 2,827 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the completion of the sale, the chief financial officer owned 19,785 shares of the company’s stock, valued at $1,770,757.50. This trade represents a 12.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,277 shares of company stock valued at $770,122 in the last 90 days. 4.90% of the stock is owned by insiders.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.